Mersana Therapeutics (NASDAQ:MRSN) Announces Quarterly Earnings Results, Beats Estimates By $0.05 EPS

Mersana Therapeutics (NASDAQ:MRSN) issued its quarterly earnings data on Monday. The company reported ($0.11) EPS for the quarter, beating analysts’ consensus estimates of ($0.16) by $0.05, Zacks reports. Mersana Therapeutics had a negative net margin of 214.20% and a negative return on equity of 401.37%. The firm had revenue of $16.36 million for the quarter, compared to analysts’ expectations of $7.71 million.

Mersana Therapeutics Stock Performance

MRSN opened at $0.48 on Tuesday. The stock has a 50-day moving average of $0.84 and a 200-day moving average of $1.57. Mersana Therapeutics has a 52-week low of $0.48 and a 52-week high of $6.28. The company has a market cap of $59.30 million, a PE ratio of -0.79 and a beta of 1.39. The company has a debt-to-equity ratio of 13.35, a quick ratio of 2.35 and a current ratio of 2.35.

Analyst Ratings Changes

MRSN has been the topic of a number of research analyst reports. Citigroup assumed coverage on Mersana Therapeutics in a report on Friday, November 15th. They issued a “buy” rating and a $5.00 target price on the stock. William Blair initiated coverage on Mersana Therapeutics in a report on Thursday, February 6th. They issued an “outperform” rating for the company. Finally, Wedbush restated an “outperform” rating and issued a $4.00 target price on shares of Mersana Therapeutics in a research note on Monday. Two equities research analysts have rated the stock with a hold rating, three have given a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $4.25.

About Mersana Therapeutics

Mersana Therapeutics, Inc, a clinical stage biopharmaceutical company, develops antibody drug conjugates (ADC) for cancer patients with unmet needs. The company develops XMT-1660, a B7-H4-targeted Dolasynthen ADC candidate; and XMT-2056, an immunosynthen ADC. It has research and development collaborations with Janssen Biotech, Inc, Ares Trading SA, Merck KGaA, and Asana BioSciences, LLC for the development of ADC product candidates.